论文部分内容阅读
目的:探讨中药组分绞股蓝总皂苷对二甲基亚硝胺(DMN)诱导的大鼠肝纤维化的防治作用。方法:采用腹腔注射DMN诱导大鼠肝纤维化模型。在造模4周后,将造模大鼠随机分为模型组、绞股蓝总皂苷组(200 mg.kg-1)及对照药秋水仙碱组(0.1 mg.kg-1),每组10只,灌胃用药2周后取材。观察检测以下指标:①末次体重、肝脾比值;②肝组织羟脯氨酸含量测定;③肝功能指标:血清丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、谷胺酰转肽酶(GGT)活性,血清白蛋白(Alb)、总胆红素(TBiL)含量;④肝组织天狼星红染色及HE染色;⑤肝组织脂质过氧化指标:超氧化物歧化酶(SOD)、丙二醛(MDA)、还原型谷胱甘肽(GSH)、谷胱甘肽过氧化物酶(GSH-Px)。结果:模型组出现典型的肝纤维化病理改变,与正常组比较,模型组肝组织Hyp含量、血清ALT,AST,GGT活性及TBiL,MDA含量显著升高,同时血清Alb含量、肝组织SOD活性、GSH含量、GSH-Px活性显著降低;较之模型组,绞股蓝总皂苷肝纤维化程度显著减轻,肝组织羟脯氨酸含量显著降低(P<0.01),与秋水仙碱组效应相当。绞股蓝总皂苷组肝功能指标均有显著改善,同时能显著升高肝组织SOD,GSH-Px活性(P<0.05),降低MDA含量。结论:绞股蓝总皂苷对DMN诱导的大鼠肝纤维化有显著的治疗作用。
Objective: To explore the preventive and therapeutic effects of gypenosides on the hepatic fibrosis induced by dimethylnitrosamine (DMN) in rats. Methods: The model of hepatic fibrosis was induced by intraperitoneal injection of DMN. Four weeks after modeling, the model rats were randomly divided into model group, gypenosides group (200 mg.kg-1) and control group, colchicine group (0.1 mg.kg-1) , Gavage medication after 2 weeks drawing. Observed and detected the following indicators: ① the last weight, liver and spleen ratio; ② liver hydroxyproline content; ③ liver function indicators: serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) (GGT) activity, serum albumin (Alb), total bilirubin (TBiL) content; ④ liver tissue Sirius red staining and HE staining; ⑤ liver tissue lipid peroxidation indicators: superoxide dismutase SOD, MDA, GSH and GSH-Px. Results: Compared with normal group, Hyp level, serum ALT, AST, GGT activity and TBiL and MDA in model group were significantly increased as compared with those in normal group. Meanwhile, serum Alb level, SOD activity in liver tissue , GSH content and GSH-Px activity were significantly decreased. Compared with model group, the degree of hepatic fibrosis of Gynostemma saponin was significantly reduced, and the content of hydroxyproline in liver tissue was significantly decreased (P <0.01), which was comparable to that of colchicine group. Gypenosides group liver function indicators were significantly improved, while significantly increased liver SOD, GSH-Px activity (P <0.05), reduce the content of MDA. Conclusion: Gypenosides has a significant therapeutic effect on DMN-induced hepatic fibrosis in rats.